top of page
Home
Technology
Pipeline
Female Stress Urinary Incontinence
About Us
Open Positions
Investors & Media
Contact
More...
Use tab to navigate through the menu items.
ALL POSTS
NEWS
MEDIA
RESOURCES
AWARDS
PUBLICATIONS
Search
MUVON Reports Positive Phase 2 Results for its First-in-Class Muscle Precursor Cell-based Tissue-Engineered Therapy Showing Significant & Clinically Meaningful Benefits in Stress Urinary Incontinence
MUVON Therapeutics Reports Positive Phase 2 Results for its First-in-Class Muscle Precursor Cell-based Tissue-Engineered Therapy Showing Statistically Significant & Clinically Meaningful Benefits in Stress Urinary Incontinence
3 days ago
4 min read
Dr. Thomas Meier elected as new Chairman of the Board of Directors at MUVON Therapeutics’ Annual General Meeting 2025
Zurich, Switzerland, July 01, 2025 – MUVON Therapeutics AG, an innovative clinical-stage biotechnology company, appoints Thomas Meier as...
Jul 1
2 min read
MUVON Completes Patient Enrollment of Randomized Phase 2 Clinical Study Evaluating Muscle Precursor Cell (MPC)-based Therapy in Stress Urinary Incontinence and Expects Topline Data in Q3 2025
Zurich, Switzerland, April 16, 2025 – MUVON Therapeutics AG, an innovative clinical-stage biotechnology company, announces dosing of the...
Apr 16
2 min read
MUVON Therapeutics Clears Phase 2 Interim Milestone and Will Participate in the 2025 J.P. Morgan Healthcare Conference
MUVON clears phase 2 interim milestone and announces participation in 2025 J.P. Morgan Healthcare Conference
Jan 9
2 min read
INVEST IN OUR
INNOVATION
MORE INFORMATION
Invest in us to be part of a groundbreaking journey toward innovative, life-changing muscle regeneration therapies, addressing a massive global market with scalable solutions.
bottom of page
